Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | PPARD | Q03181 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 12/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 6/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5801147 | 0.91 | HPGD (0.60) | HPGDPPARDMAOBALDH1A1MAPK1 | |
| SCHEMBL12732188 | 0.90 | HPGD (0.80) | HPGDPPARDALDH1A1MAPK1CYP3A4 | |
| SCHEMBL2012737 | 0.88 | HPGD (0.59) | HPGDPPARDMAOBALDH1A1MAPK1 | |
| SCHEMBL2013386 | 0.87 | HPGD (0.56) | HPGDALDH1A1MAPK1CYP3A4GAA | |
| SCHEMBL7472541 | 0.86 | HPGD (0.67) | HPGDALDH1A1MAPK1GAAHSD17B10 | |
| SCHEMBL10684071 | 0.85 | PPARD (0.63) | HPGDPPARDMAOBALDH1A1MAPK1 | |
| SCHEMBL2013048 | 0.85 | HPGD (0.65) | HPGDPPARDMAOBALDH1A1MAPK1 | |
| SCHEMBL2004229 | 0.85 | HPGD (0.65) | HPGDPPARDALDH1A1MAPK1CYP3A4 | |
| SCHEMBL29012498 | 0.85 | MAOB (0.62) | HPGDPPARDMAOBALDH1A1MAPK1 | |
| SCHEMBL429049 | 0.84 | MAOB (0.67) | HPGDPPARDMAOBALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-1677783-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | Nicholas Piramal India Limited (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005035495-A2 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2005-04-21 | — | — | WO | disclosed |
| US-RE33109-E | ANTIULCER, ANTIINFLAMMATORY | BIOREX LABORATORIES LIMITED (GB) | 1989-11-07 | — | — | US | disclosed |
| US-4782176-A | ANTIALLERGY | HOFFMANN-LA ROCHE INC. (US) | 1988-11-01 | — | — | US | disclosed |
| US-4656305-A | ANTIINFLAMMATORY AND ANTIULCER AGENTS; ANTIALLERGENS; ANALGESICS | BIOREX LABORATORIES, LIMITED (GB) | 1987-04-07 | — | — | US | disclosed |
| US-4507498-A | Phenoxycarboxylic acids | HOFFMANN-LA ROCHE INC. (US) | 1985-03-26 | — | — | US | disclosed |
| US-3956375-A | 1,3-Diphenyl-propanone-1-derivatives and the salts thereof | CHINOIN GYOGYSZER-ES VEGYESZETI TERMEKEK GYARA RT (HU) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | HPGD 1551/4885PPARD 948/4885MAOB 1394/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | HPGD 1551/4885PPARD 948/4885MAOB 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.